TCT 2022: Trial Of Boston Scientific’s TAVR Embolic Protector Misses Endpoint, But May Offer 'Hope'
Executive Summary
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.
You may also be interested in...
Cardiovascular Catch-Up: Cardiac Implants Puts Ring Around Tricuspid Annulus; Boston Scientific’s Acurate neo2 TAVR Progresses; Medtronic Promotes New Stroke Plan
This edition of Medtech Insight’s regular round-up of some recent cardiovascular technology news and conversations you may have missed, including updates from Cardiac Implants, Boston Scientific, HeartBeam and Medtronic.
TCT 2022: Edwards Ready To Take On Abbott In Mitral Repair Market With ‘Premium’ Device
Edwards Lifesciences is ramping up US commercialization of its Pascal Precision mitral valve transcatheter edge-to-edge repair device, the first US competitor for Abbott’s MitraClip. The FDA approved Pascal Precision earlier than the company expected, based on results of the CLASP IID trial.
TCT 2022: Edwards' Pascal Matches Abbott's MitraClip In CLASP IID
Results of the CLASP IID trial showed Edwards’ Pascal mitral valve repair system was non-inferior for safety and effectiveness compared to Abbott’s MitraClip device.